Does methadone inhibit cytochrome P450 enzymes (e.g., CYP3A4, CYP2D6, CYP2B6, CYP2C19, CYP2C9)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Methadone as a Cytochrome P450 Inhibitor

Yes, methadone does inhibit certain cytochrome P450 enzymes, most notably CYP2D6 and potentially CYP3A4, though it is primarily a substrate rather than a clinically significant inhibitor of most CYP enzymes.

Methadone's Role: Primarily a CYP Substrate

The FDA drug label clearly establishes that methadone is metabolized by (not an inhibitor of) multiple CYP enzymes 1. Specifically, methadone undergoes hepatic N-demethylation primarily via:

  • CYP3A4 (principal enzyme)
  • CYP2B6 (principal enzyme)
  • CYP2C19 (principal enzyme)
  • CYP2C9 (lesser extent)
  • CYP2D6 (lesser extent)

This means methadone is vulnerable to drug interactions when combined with CYP inducers (which accelerate its metabolism and may cause withdrawal) or CYP inhibitors (which slow its metabolism and may cause toxicity) 1.

Evidence for Methadone as an Inhibitor

CYP2D6 Inhibition (Clinically Relevant)

Methadone does inhibit CYP2D6 in vivo, despite not being a substrate of this enzyme 2. A 2012 study demonstrated that methadone-maintained patients had:

  • Significantly impaired CYP2D6-mediated O-demethylation of codeine (metabolic ratio 2.8 ± 3.1 vs. 0.60 ± 0.43 in buprenorphine controls, P=0.0044)
  • Reduced formation of morphine-6-glucuronide (the active analgesic metabolite)
  • This inhibition occurred even though methadone is not metabolized by CYP2D6 2

Clinical implication: Patients on methadone may have reduced analgesic response to codeine and tramadol (both CYP2D6-dependent prodrugs) 3.

CYP3A4 Inhibition (Moderate, In Vitro)

A 1997 in vitro study showed methadone inhibits CYP3A4-mediated nifedipine oxidation with a Ki of 100 μM through mixed-type inhibition 4. However, this is a moderate inhibitory effect and the clinical significance is limited compared to methadone's role as a CYP3A4 substrate.

UGT2B7/2B4 Inhibition

Methadone also inhibits UGT2B7 and UGT2B4 glucuronidation pathways in vivo 2, which affects the metabolism of drugs dependent on these enzymes.

Clinical Management Algorithm

When Prescribing Methadone:

  1. Avoid combining with CYP2D6 prodrugs (codeine, tramadol) as methadone will reduce their conversion to active metabolites and diminish analgesia 3, 2

  2. Monitor for methadone toxicity when adding CYP3A4/2B6/2C19 inhibitors:

    • Examples: Fluvoxamine (Ki=7 μM for methadone metabolism), certain antiretrovirals, azole antifungals 1, 4
    • May require methadone dose reduction
  3. Anticipate withdrawal when adding CYP inducers:

    • Rifampin, phenytoin (causes ~50% reduction in methadone exposure), carbamazepine, St. John's Wort 1
    • May require methadone dose increase or more frequent dosing
  4. Methadone should only be prescribed by experienced clinicians due to its complex pharmacokinetics 5

Key Caveats

  • Genetic polymorphisms matter: CYP2B6*6/*6 carriers have significantly reduced methadone clearance and higher plasma concentrations, increasing toxicity risk 6, 7
  • The half-life varies widely (7-59 hours), making dose adjustments unpredictable 1
  • Methadone's lipophilic nature causes tissue accumulation, prolonging effects beyond plasma levels 1
  • Pregnancy increases methadone clearance, potentially requiring dose increases 1

Bottom line: While methadone is predominantly a CYP substrate (making it vulnerable to interactions), it does clinically inhibit CYP2D6 and UGT enzymes, which must be considered when combining with other medications metabolized by these pathways.

Related Questions

Given the patient's pharmacogenomic profile (ADRA2A heterozygous, HLA‑A*3101 absent, HLA‑B*1502 absent, HTR2A G/G, SLC6A4 short/long heterozygous, CES1A1 normal metabolizer, CYP1A2 A/A, CYP2B6 normal, CYP2C19 normal, CYP2C9 intermediate, CYP2D6 normal, CYP3A4 normal, UGT1A4 ultrarapid, UGT2B15 intermediate, MTHFR heterozygous C/T, COMT Val/Met), what are the recommended pharmacologic treatment choices and dosing adjustments for ADHD, depression/anxiety, and other relevant conditions?
What alternative treatments should be considered for a patient who did not respond to sertraline (Zoloft)?
How does escitalopram contribute to nightmares and vivid dreams, and will a slow taper of escitalopram reduce these sleep disturbances in a patient already taking lamotrigine 25 mg nightly?
Which antidepressants have the least sedating effect?
In a 68-year-old man currently taking duloxetine who is experiencing increased agitation and anxiety, is it safe or feasible to increase the duloxetine dose to 80 mg?
What is the difference between a random urine albumin-to-creatinine ratio (ACR) and the albumin-to-creatinine ratio (ACR)?
Are shortness of breath and cough side effects of losartan (angiotensin‑II receptor blocker) and hydrochlorothiazide (thiazide diuretic)?
In a post‑coronary artery bypass grafting patient, should metoprolol be initiated as the tartrate (immediate‑release) or succinate (extended‑release) formulation?
What bacterial pathogens does cefuroxime cover in community-acquired pneumonia, and what additional therapy is needed for atypical organisms?
What is the safe weight‑based dosing range of dicyclomine for children older than six months (mg per kilogram per dose)?
What is the metabolic pathway of Suboxone (buprenorphine/naloxone)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.